pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 28·1 min read
save

Mirae secures $5.4 million to convert patient chatbot messages into clinical data

Jul 28, 2026·read at Endpoints ↗DealPositive

Mirae, a health‑tech startup, announced it has closed a financing round that brought in $5.4 million.

The capital will be used to develop its chatbot platform that encourages patients to describe their symptoms via text, turning those conversations into structured data for physicians.

By converting informal patient messages into actionable information, the company aims to help doctors make more informed treatment decisions.

The funding round highlights growing investor interest in AI‑driven tools that bridge patient communication and clinical insight.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Mirae raises $5.4M to turn patient texts into data for doctors”

read at Endpoints ↗
88 words · retrieved Jul 28
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoSummit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialEndpoints
  • 3h agoSuperluminal secures $60M for Phase 1 of genetic obesity drugEndpoints
  • 3h agoGSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfrontEndpoints
  • 11h agoUltragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patientsEndpoints
  • 18h agoFDA leaders project enhanced scrutiny of foreign dataEndpoints